Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate CancerMatti Annala, Alexander W. Wyatt, Kim N. et al.|European Urology|2017Cited by 218
Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate CancerJonathan Chou, Rahul Aggarwal|Cancer Research|2022Cited by 58
<sup>68</sup>Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with<sup>18</sup>F-FDGBrad Kline, Thomas A. Hope, Surekha Yadav et al.|Journal of Nuclear Medicine|2024Cited by 36
Initial Experience with<sup>68</sup>Ga-FAP-2286 PET Imaging in Patients with Urothelial CancerVadim S. Koshkin, Thomas A. Hope, Brad Kline et al.|Journal of Nuclear Medicine|2024Cited by 26
A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i> <i>-</i> Altered Advanced Solid Tumor Malignancies (NCI 10170)Edward Maldonado, Rahul Aggarwal|Cancer Research Communications|2024Cited by 12